ClinicalTrials.gg
Not yet recruitingNCT07900646Updated Oct 28, 2026

Peri-procedural Weighted Blanket Use for ECT

An interventional study of Weighted blanket and Usual Care Group in Post-ect Agitation and Post-ictal Agitation, sponsored by Mayo Clinic. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Prevention

Updated Oct 28, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if weighted blanket use before and after electroconvulsant therapy (ECT) works to reduce pre-ECT anxiety and post-ECT agitation.

The main questions it aims to answer are:

Does weighted blanket use before and after ECT reduce patient reported anxiety before ECT? Does weighted blanket use before and after ECT reduce post-ECT agitation following ECT?

Participants will:

Use either a weighted blanket or a non-weighted blanket before and after ECT. Report their anxiety before ECT Be observed for post-ECT agitation as they awaken from anesthesia after ECT.

Read the detailed description

Study design: Pilot Crossover design RCT

Method of enrollment: Informed written consent from either the patient or their LAR will be obtained by the study coordinator(s) prior to enrollment.

Subjects and recruitment methods: Enrolled patients will be computer randomized in 1:1 ratio to either receive the weighted blanket with their first observed ECT (Sequence A) or usual care first (Sequence B). If the patient undergoes multiple observed ECTs during the study period, then patients will alternate between receiving the intervention and receiving usual care.

Primary outcome measures:

  1. Post-ictal agitation (PIA) score (1 = calm or asleep, 2 =rest less but calmed down when talked to, 3=restless and required a nurse to stand next to the bed, 4=one or more nurses were required to physically hold down the patient).

    Secondary outcome measures:

  2. Maximum RASS score (Richmond Agitation-Sedation Scale)
  3. Need for medications to manage post-ictal agitation (prescribed after ECT in response to PIA and not part of the original medication orders prior to ECT) (Y/N).
  4. Change in visual analog anxiety scale before and after weighted blanket use in the pre-ECT waiting area
02

Conditions studied

  • Post-ect Agitation
  • Post-ictal Agitation

Browse trials for

Keywords

  • ect
  • weighted blankets
03

In context

Epilepsy, Rolandic

23 studies on the registry are indexed under Epilepsy, Rolandic; 3 are open to participants now.

This study's planned enrollment of 200 is above the median of 44 across 13 interventional studies indexed under Epilepsy, Rolandic.

Browse Epilepsy, Rolandic studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,269 studies on the registry; 672 are open to participants now.

Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized
  • Undergoing induction series of ECT

Exclusion criteria

Exclusion Criteria:

  • Unable to complete visual analog anxiety assessment scale
  • Court-ordered ECT
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Weighted blanket

    Intervention - 1. Patient (or their LAR) will be informed of the study and asked to sign a consent form if willing to participate. 2. Patient will arrive to the pre-ECT area and complete a visual analog anxiety scale prior to weighted blanket placement (10 lbs for patients weighing \>100 lbs, 5 lb blanket for those weighing less than 100 lbs) 3. Patient will wear the weighted blanket for at least 15 minutes in the pre-ECT area 4. Patient will complete a visual analog anxiety scale upon removal of the weighted blanket prior to ECT 5. Patient will complete a brief survey regarding their experience of the weighted blanket as the weighted blanket is removed in preparation for ECT 6. In the PACU area, weighted blanket will again be placed as long as this is felt to be safe from an RN perspective. 7. PACU RN will rate degree of post-ECT agitation (if any) and report whether PRN medications for agitation were required

    Other: Weighted blanket

  • Placebo comparator
    Usual care

    Usual care - 1. Patient (or their LAR) will be informed of the study and asked to sign a consent form if willing to participate. 2. Patient will not receive the weighted blanket. They will be offered either room temperature non-weighted blanket or warm non-weighted blanket as per usual care. 3. Patient will complete a visual analog anxiety scale before and after non-weighted blanket use. 4. PACU RN will rate degree of post-ECT agitation (if any) and report whether PRN medications for agitation were required

    Other: Usual Care Group

Interventions

  • OtherWeighted blanket

    Weighted blankets, a form of deep pressure stimulation, have been shown to be an effective non-pharmacologic means of improving anxiety in psychiatric, pediatric, geriatric, and oncologic populations.

  • OtherUsual Care Group

    Patients receiving usual care will receive non-weighted blankets

06

What researchers measure

Primary outcomes

  1. Post-ictal agitation score

    Post-ictal agitation (PIA) score (1 = calm or asleep, 2 =rest less but calmed down when talked to, 3=restless and required a nurse to stand next to the bed, 4=one or more nurses were required to physically hold down the patient).

    Time frame: In PACU immediately after ECT.

Secondary outcomes

  1. Maximum RASS score (Richmond Agitation-Sedation Scale)

    RASS score is used to evaluation level of agitation/sedation.

    Time frame: In PACU immediately after ECT.

  2. Need for medications to treat post-ECT agitation

    We will record if any additional sedating medications were needed in the PACU to treat post-ECT agitation

    Time frame: PACU

  3. Pre-ECT anxiety

    We will calculate the change in visual analog anxiety scale reported by patients before and after weighted blanket use in the pre-ECT waiting area

    Time frame: Pre-ECT waiting area

07

Study locations

1 site
08

References and documents

Publications

  • Ertman M, van der Valk Bouman ES, Clephas PRD, Birkenhager TK, Klimek M. Prognostic Factors and Incidence for Postictal Agitation After Electroconvulsive Therapy: A Systematic Review and Meta-analysis. J ECT. 2025 Mar 1;41(1):17-26. doi: 10.1097/YCT.0000000000001032. Epub 2024 Aug 22. PubMed 39105589 ↗
  • Dickson DA, Gantt L, Swanson M. Effectiveness of the Weighted Blanket With Psychiatric Patients in the Emergency Department: A Pilot Study. J Am Psychiatr Nurses Assoc. 2023 Jul-Aug;29(4):307-313. doi: 10.1177/10783903211026740. Epub 2021 Jun 24. PubMed 34166155 ↗
  • Allen ND, Allison CL, Golebiowski R, Janowski JPB, LeMahieu AM, Geske JR, Rasmussen KG. Factors Associated With Postictal Agitation After Electroconvulsive Therapy. J ECT. 2022 Mar 1;38(1):60-61. doi: 10.1097/YCT.0000000000000807. PubMed 34739422 ↗

Individual participant data

Plan to share: No — All patient data will be de-identified.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2026
First posted
Oct 28, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07900646
Lead sponsor
Mayo Clinic
Responsible party
Ruth E Bates (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Oct 28, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Ruth DeFoster, MD
Contact
DeFoster.ruth@mayo.edu
507-255-8716

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion